Supernitro is under clinical development by Attgeno and currently in Phase I for Pulmonary Embolism. According to GlobalData, Phase I drugs for Pulmonary Embolism have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Supernitro’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Supernitro overview
Supernitro is under development for the treatment of chronic pulmonary hypertension (pulmonary hypertension) and acute pulmonary hypertension induced by pulmonary embolism. The drug candidate is nitrogen oxide (NO) containing compound. It consists of propylene glycol (1,2-propanediol, PD) chemically combined with NO. It is administered through intravenous route.
Attgeno overview
Attgeno is a Swedish pharmaceutical company that develops nitric oxide donor, Supernitro to treat acute pulmonary hypertension. The company mainly based on ground-breaking research on nitric oxide and circulatory physiology. Supernitro, the first drug candidate, represents a great new step in the medical use of nitric oxide. The drug is developed to selectively widen the blood vessels in the lungs. Supernitro as an intravenous infusion which means that nitric oxide is delivered in the natural way via the blood-vessels to the heart and lungs. Attgeno is headquartered in Solna, Stockholm, Sweden.
For a complete picture of Supernitro’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
